v3.26.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Series C-1 Preferred Stock [Member]
Preferred Stock [Member]
Series C One Preferred Stock Mezzanine [Member]
Preferred Stock [Member]
Series C Two Preferred Stock Mezzanine [Member]
Preferred Stock [Member]
Series C-2 Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 $ 7,457,000     $ 49,537,090 $ (67,327,733) $ 12,584,358
Balance, shares at Dec. 31, 2024 3,116 30,375 8,576          
Reclassification of C-1 Preferred Stock $ (30,375,000) $ 30,375,000       (30,375,000)
Balance, shares   (30,375) 30,375            
Proceeds from the sale of common stock, net of fees and expenses     8,747,902 8,747,902
Balance, shares 1,814                
Preferred stock redemption $ (3,478,078)     (521,922) (521,922)
Preferred stock redemption, shares       (4,000)          
Warrant exercise - cashless    
Balance, shares 73                
Warrant exercise - prefunded     88 88
Balance, shares 1,224                
Stock options issued to directors and employees     70,655 70,655
Dividends on preferred stock     (305,245) (305,245)
Rounding for reverse split    
Balance, shares 2                
Net loss attributable to Invo Bioscience, Inc     (17,403,586) (17,403,586)
Balance at Mar. 31, 2025 $ 1 $ 30,375,000 $ 3,978,922     57,833,813 (85,036,564) (27,202,750)
Balance, shares at Mar. 31, 2025 6,229 30,375 4,576          
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 $ 7,457,000     49,537,090 (67,327,733) 12,584,358
Balance, shares at Dec. 31, 2024 3,116 30,375 8,576          
Net loss attributable to Invo Bioscience, Inc                 (21,022,555)
Balance at Jun. 30, 2025 $ 3 $ 10,121,922     81,547,227 (88,700,467) (7,153,237)
Balance, shares at Jun. 30, 2025 20,713 10,719          
Balance at Mar. 31, 2025 $ 1 $ 30,375,000 $ 3,978,922     57,833,813 (85,036,564) (27,202,750)
Balance, shares at Mar. 31, 2025 6,229 30,375 4,576          
Warrant exercise - cashless    
Balance, shares 319                
Warrant exercise - prefunded $ 1     799 800
Balance, shares 6,419                
Stock options issued to directors and employees     11,875 11,875
Dividends on preferred stock     (44,934) (44,934)
Net loss attributable to Invo Bioscience, Inc     (3,618,969) (3,618,969)
Common stock issued to service providers     62,265 62,265
Balance, shares 254                
Debt conversion $ 2,430,000     (178,666) (178,666)
Debt conversion, shares 2,193     2,430          
Warrant exercise $ 1     286,852 286,853
Balance, shares 5,299                
C-1 to C-2 exchange $ (2,025,000) $ 3,213,000     (837,821) (837,821)
C-1 to C-2 exchange, shares     (2,025) 3,213          
Divesture of NAYA $ (28,350,000)     24,368,110 24,368,110
Divesture of NAYA, shares     (28,350)            
Proceeds from the sale of preferred stock $ 500,000    
Proceeds from the sale of preferred stock, shares       500          
Balance at Jun. 30, 2025 $ 3 $ 10,121,922     81,547,227 (88,700,467) (7,153,237)
Balance, shares at Jun. 30, 2025 20,713 10,719          
Balance at Dec. 31, 2025 $ 47       $ 2,406,359 96,187,218 (91,369,403) 7,224,221
Balance, shares at Dec. 31, 2025 477,377       3,004      
Warrant exercise - cashless $ 8       346,898 346,906
Balance, shares 84,730                
Warrant exercise - prefunded $ 43       171 214
Balance, shares 426,373                
Stock options issued to directors and employees       94,311 94,311
Dividends on preferred stock       23,000 (15,604) 7,396
Rounding for reverse split      
Balance, shares 203                
Net loss attributable to Invo Bioscience, Inc       (5,539,351) (5,539,351)
Common stock issued to service providers $ 3       70,918 70,921
Balance, shares 25,000                
Warrant exercise $ 51       12,418,977 12,419,028
Balance, shares 506,546                
Preferred stock conversion $ 12       $ (2,429,359) 2,429,347
Balance, shares 120,406       3,027        
Balance, shares         23        
Consideration in acquisition       $ 400,000 400,000
Balance, shares           400      
Balance at Mar. 31, 2026 $ 164       $ 400,000 111,547,840 (96,924,358) 15,023,646
Balance, shares at Mar. 31, 2026 1,640,635       400      
Balance at Dec. 31, 2025 $ 47       $ 2,406,359 96,187,218 (91,369,403) 7,224,221
Balance, shares at Dec. 31, 2025 477,377       3,004      
Net loss attributable to Invo Bioscience, Inc                 (4,650,611)
Debt conversion, shares         120,406        
Balance at Jun. 30, 2026 $ 229       $ 400,000 112,126,967 (96,035,618) 16,491,578
Balance, shares at Jun. 30, 2026 2,295,035       400      
Balance at Mar. 31, 2026 $ 164       $ 400,000 111,547,840 (96,924,358) 15,023,646
Balance, shares at Mar. 31, 2026 1,640,635       400      
Stock options issued to directors and employees       94,311 94,311
Net loss attributable to Invo Bioscience, Inc       888,740 888,740
Common stock issued to service providers $ 1       24,259 24,260
Balance, shares 15,000                
Warrant exercise $ 46       (46)
Balance, shares 459,400                
Warrants issued with debt       172,621 172,621
Note conversion $ 18       287,982 288,000
Balance, shares 180,000                
Balance at Jun. 30, 2026 $ 229       $ 400,000 $ 112,126,967 $ (96,035,618) $ 16,491,578
Balance, shares at Jun. 30, 2026 2,295,035       400